# Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma

> **NCT07476794** · PHASE2 · RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 118 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Daily TMZ

## Key facts

- **NCT ID:** NCT07476794
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-10
- **Final completion:** 2029-11
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476794, "Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07476794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*